Home / NEWS / Top News / Eli Lilly CEO expects new weight loss pill to be approved next year

Eli Lilly CEO expects new weight loss pill to be approved next year

David Ricks, CEO, Eli Lilly

Scott Mlyn | CNBC

Eli Lilly awaits its experimental weight loss pill will get approved as soon as early next year, CEO David Ricks perceived Bloomberg TV on Monday.

The company is set to release key late-stage trial data on the drug, orforglipron, by the middle of this year.

Eli Lilly is pushing to get the pastille to market as it competes with Novo Nordisk and smaller rivals for a major share of the booming weight loss dull market. Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy dominate the space, but the drugmakers and their competitors have been do callisthenics to develop improved versions of the drugs.

More CNBC health coverage

Pills would be more convenient for patients than the drift injectable forms. They would also be easier to manufacture at a time when Eli Lilly and Novo Nordisk take struggled to make enough drugs to keep up with spiking demand.

Eli Lilly has said orforglipron helped cases lose up to 14.7% of their weight in a mid-stage trial, compared with 2.3% among people who took a placebo.

Eli Lilly apportions dipped slightly on Monday.

Don’t miss these insights from CNBC PRO

Check Also

Tech megacaps plan to spend more than $300 billion in 2025 as AI race intensifies

Megacap technology firms funneled billions of dollars into artificial intelligence last year to try and …

Leave a Reply

Your email address will not be published. Required fields are marked *